Vera Therapeutics, Inc. Deferred Offering Costs
Vera Therapeutics, Inc. (VERA) had Deferred Offering Costs of $400.00 thousand as of 2023-02-06, per its 10-Q filed 2023-11-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2023-11-09
- 2023-02-06: Deferred Offering Costs $400.00K.
- 2022-02-14: Deferred Offering Costs $900.00K.
- 2022-02-09: Deferred Offering Costs $900.00K; Deferred Offering Costs as first filed $800.00K.
- 2021-05-20: Deferred Offering Costs $2.80M.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2023-02-06 | $400.00K 10-Q · filed 2023-11-09 | |
| 2022-02-14 | $900.00K 10-Q · filed 2023-11-09 | |
| 2022-02-09 | $900.00K 10-K · filed 2023-03-28 | $800.00K 10-Q · filed 2022-05-16 |
| 2021-05-20 | $2.80M 10-Q · filed 2023-11-09 | |
| 2021-03-31 | $1.29M 10-Q · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |